LOS ANGELES, May 8, 2024 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire" or the "Company"), an innovator in vaping technology and precision dosing, announced today that it will host its earnings conference call at 8:00 am ET on Wednesday, May 15, 2024, to discuss the Company's financial results for its fiscal third quarter ended March 31, 2024. To attend the conference call, please dial in using the information below. When prompted upon dialing-in, please ask for the "Ispire Technology Call. ...

Company to Supply Multi-State Cannabis Operator with Comprehensive Solution to Streamline Vape Production: Ispire ONE™ LOS ANGELES, April 30, 2024 /PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire" or the "Company"), an innovator in vaping technology and precision dosing, announced it has signed an agreement with a subsidiary of Acreage Holdings, Inc. ("Acreage"), a publicly traded, vertically integrated, multi-state operator of cannabis cultivation and retailing facilities in the United State ...

As filed with the U.S. Securities and Exchange Commission on March 18, 2024. Registration No. 333-276804 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _________________________ ISPIRE TECHNOLOGY INC. (Exact name of registrant as specified in its charter) _________________________ Delaware 2111 93-1869878 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Clas ...

Total Revenue Increased 30.7% to $41.7 Million Gross Profit Increased 24.1% to $6.4 Million North American Cannabis Vaping Hardware Revenue Increased 149% to $19.5 Million Los Angeles, Calif. February 20, 2024 - Ispire Technology Inc. ("Ispire" or "the Company") (NASDAQ: ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, today reported results for the fiscal second quarter, which ended December 31, 2023, and filed its quarterly report on Form 10-Q ...

Financial Performance - Revenue for the three months ended December 31, 2023, increased to $41,685,561, representing a 30.6% growth compared to $31,897,399 in the same period of 2022[16] - Gross profit for the six months ended December 31, 2023, was $13,264,498, up from $9,930,681 in the prior year, indicating a 33.5% increase[16] - Total revenue for the three months ended December 31, 2023, was $35,309,000, an increase from $31,897,000 for the same period in 2022, representing a growth of 10.5%[141] - Revenue increased by $9.79 million, or 30.7%, from $31.90 million for the three months ended December 31, 2022, to $41.69 million for the same period in 2023[136] - Revenue for the six months ended December 31, 2023, increased by $25.71 million, or 43.7%, from $58.84 million to $84.55 million[137] - Revenue from tobacco vaping products decreased to $22,134,264 in Q4 2023 from $24,061,401 in Q4 2022, while revenue from cannabis vaping products increased significantly to $19,551,297 from $7,835,998[63] Expenses and Losses - Operating expenses for the three months ended December 31, 2023, rose to $10,326,842, a significant increase from $4,828,735 in the same period of 2022, reflecting a 113.1% rise[16] - The company reported a net loss of $4,022,324 for the three months ended December 31, 2023, compared to a net loss of $130,242 in the same period of 2022[72] - The net loss for the six months ended December 31, 2023, was $5,396,939, compared to a net loss of $2,131,996 for the same period in 2022, representing a 153.1% increase in losses[22] - Net loss for the three months ended December 31, 2023, was $4.02 million, or 9.6% of revenue[133] - Operating expenses increased by $5,498,107, or 113.9%, from $4,828,735 for the three months ended December 31, 2022, to $10,326,842 for the same period in 2023[144] Assets and Liabilities - Cash and cash equivalents decreased to $17,502,989 as of December 31, 2023, down from $84,267,154 at the end of the previous year, marking a decline of 79.2%[22] - Total liabilities increased to $61,592,891 as of December 31, 2023, up from $59,318,416 at the end of June 30, 2023, reflecting a growth of 3.8%[18] - The company’s total stockholders' equity decreased to $28,987,264 as of December 31, 2023, down from $31,374,933 at the end of June 30, 2023, a decline of 7.6%[18] - Current assets decreased by $1,803,000, or 2.1%, from $84,811,000 as of June 30, 2023, to $83,008,000 as of December 31, 2023[155] - Contract liabilities increased from $988,556 as of June 30, 2023, to $1,705,171 as of December 31, 2023, indicating more orders on hand[91] Operational Developments - Ispire Technology Inc. is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products[23] - The Company established a wholly-owned subsidiary, Ispire Malaysia, on September 1, 2023, to enhance manufacturing operations in Southeast Asia[27] - The Company has submitted a Premarket Tobacco Product Application (PMTA) for one ENDS product, pending FDA review, which could impact market access[38] - The Company ceased marketing tobacco vaping products in the U.S. due to regulatory burdens, as the sales volume did not justify the associated costs[39] - Supply chain issues previously affected operations, but current conditions have improved, reducing delays in product delivery[33] Risk Factors - Cybersecurity remains a significant risk, with potential impacts on financial condition and operations due to increasing cyber threats[174] - The Company’s operations are subject to uncertainties related to COVID-19, particularly concerning manufacturing in China[32] - The company has not identified any trends or uncertainties that could materially affect its financial performance[167] - Seasonality does not materially affect the company's business operations[168] Shareholder Information - The weighted average basic and diluted shares outstanding increased to 54,270,236 for the three months ended December 31, 2023, from 50,000,000 in the same period of 2022[72] - The company granted 2,910,000 stock options with a weighted average exercise price of $9.63 during the six months ended December 31, 2023[107] - The aggregate intrinsic value of options outstanding as of December 31, 2023, was $7,263,425, with $400,875 for options exercisable[107] Management and Governance - The company has appointed a new chief financial officer and a vice president of finance to address material weaknesses in internal control[177] - The company qualifies as an "emerging growth company" under the JOBS Act, with revenues below $1.235 billion for the last fiscal year, allowing it to take advantage of reduced reporting requirements[173] - The company does not have off-balance sheet arrangements, indicating a straightforward financial structure[169]

As filed with the U.S. Securities and Exchange Commission on February 1, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 _________________________ ISPIRE TECHNOLOGY INC. (Exact name of registrant as specified in its charter) _________________________ (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2111 93-1869878 ...

Summary of the Conference Call Company Overview - The company is a unique player in the cannabis industry, being the first publicly listed company in the U.S. focused on cannabis vaporization [1] - The company operates in a rapidly growing market, with the U.S. cannabis market valued at $100 billion in 2022, and projected to reach $200 billion by 2027 [1][1] - The company has a strong technological background, with its founder having over a decade of experience in the electronic vaporization industry [1] Market Dynamics - The cannabis vaporization market has a penetration rate of approximately 25%, equating to $25 billion in vaporization products [1] - The company emphasizes the importance of localizing its operations, including R&D, testing, and production, to better meet customer needs and regulatory requirements [1] - The company has established production lines in the U.S. and Malaysia to enhance its gross margin, which is expected to recover to 30%-35% within 16-18 months [1] Legislative Environment - The C4 Banking Act, which would allow cannabis businesses to access banking services, has passed the Senate Finance Committee and is awaiting a full Senate vote [1] - The U.S. Department of Health and Human Services has submitted a report to reclassify cannabis from a Schedule I to a Schedule III controlled substance, which is seen as a significant step towards legalization [1] Financial Performance - The company reported revenues of $115 million in 2023, with $70 million from electronic cigarettes and $40 million from cannabis devices [1] - The company anticipates revenues of $80-$90 million from cannabis products in the fiscal year ending June 30, 2024, with a potential to exceed $100 million based on current trends [1] - The company is expected to achieve profitability in 2024, with projected profits of over $10 million if sales reach $100 million [1] Competitive Advantages - The company holds over 200 patents in the cannabis industry, ensuring a competitive edge in technology and product development [1] - The company has established strong relationships with cannabis brands, allowing for collaborative product development and distribution [1] Risks and Challenges - The company does not operate in the Chinese market due to regulatory constraints and geopolitical risks [1] - The cannabis industry faces challenges related to cash transactions and banking access, which the C4 Banking Act aims to address [1] Conclusion - The company is well-positioned in a growing market with significant potential for expansion and profitability, driven by legislative changes and strong local operations [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41680 Ispire Technology Inc. (Exact name of registrant as specified in its charter) Delaware 93-1869878 (State or other jurisdiction of inco ...

As filed with the Securities and Exchange Commission on October 18, 2023. Registration No. 333-273904 (Name, address, including zip code, and telephone number, including area code, of agent for service) Richard I. Anslow, Esq. Jonathan Deblinger, Esq. Asher S. Levitsky P.C. Ellenoff Grossman & Schole LLP 1345 Avenue of the Americas; Suite 1100 New York, New York 10105 Telephone: (212) 370-1300 Approximate date of commencement of proposed sale to the public: as soon as practicable after the effective date of ...

As filed with the Securities and Exchange Commission on October 10, 2023. Registration No. 333-273904 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2111 84-5106049 (I.R.S. Employer Identification Number) 19700 Magellan Drive Los Angeles, CA 90502 (310) 742-9975 (Address, including zip c ...